Comparison · NCT01617096-sae
Dapivirine Vaginal Ring vs Placebo Ring: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dapivirine Vaginal Ring vs Placebo Ring: serious adverse events. Trial comparisons, record NCT01617096-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01617096-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0883 | 0.0742 | 0.105 | wilson | |
| Risk in group 2 | 0.0988 | 0.0838 | 0.116 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0104 | -0.0328 | 0.0119 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.894 | 0.705 | 1.14 | log | |
| Odds ratio, group 1 over group 2 | 0.884 | 0.68 | 1.15 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Dapivirine Vaginal Ring than on Placebo Ring | 95.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dapivirine Vaginal Ring | Vaginal ring containing 25mg dapivirine~Dapivirine Vaginal Ring: Dosage form: vaginal ring Dosage: 25mg Frequency: monthly Duration: 12 months | 116 | 1,313 | EG000 |
| Group 2 | Placebo Ring | Vaginal ring containing no drug substance~Placebo Ring: Vaginal ring containing no drug substance | 130 | 1,316 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 24 Months
Source ClinicalTrials.gov
Trial
- Title
- Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women
- NCT number
- NCT01617096
- Phases
- PHASE3
- Conditions
- HIV Infections
- Interventions
- Dapivirine Vaginal Ring, Placebo Ring
- Lead sponsor
- International Partnership for Microbicides, Inc.
- Results first posted
- 2022-12-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01617096?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01617096-sae